Evidence map›Paper›PMID 41278443›Full record

ArticleWorld journal of diabetes2025

Glucagon-like peptide 1 receptor agonists switching patterns in type two diabetes: A retrospective real-world study.

Sameer Kassem, Buthaina Khalaila, Nili Stein, Adnan Zaina

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sameer KassemDepartment of Internal Medicine, Technion Israel Institute of Technology, Haifa 3436212, Israel. sameerk@technion.ac.il.
Buthaina KhalailaDepartment of Pharmacology, Clalit Health Services, Haifa 3436212, Israel.
Nili SteinDepartment of Epidemiology, Clalit Health Services, Haifa 3436212, Israel.
Adnan ZainaDepartment of Endocrinology, Bar Ilan University, Haifa 3436212, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlucagon-like peptide-1 receptor agonists (GLP-1RAs) play a key role in managing type 2 diabetes mellitus (T2DM). Transitioning between different GLP-1RA has been proposed as a treatment strategy.

aimTo investigate switching patterns between GLP-1RA and their impact on glycemic control.

methodsA retrospective study involving patients with T2DM who initiated GLP-1RA therapy between 2009 and 2021 and transitioned to another GLP-1RA. Baseline glycated hemoglobin (HbA

resultsAmong 70654 patients initiating GLP-1RA therapy, 18047 (25.5%) switched regimens. In the 13970 patients with available HbA

conclusionSwitching between GLP-1RAs can serve as a practical alternative to treatment intensification for effectively managing T2DM.

Indexed as

Glucagon-like peptide-1 receptor agonistsGlycated hemoglobinGlycemic controlReal worldSwitchingType 2 diabetes mellitus

Identifiers

PMID41278443
PMCPMC12635781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.